Visuals
Sidebar
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That ...
Ambient Artificial Intelligence Clinical Documentation: Workflow Support with Emerging Governance Risk
Health systems are increasingly deploying ambient artificial intelligence tools that listen to clinical encounters and automatically generate draft visit notes. ...
What the Most-Cited LLM-in-Medicine Papers Reveal—and What They Miss
In just over two years, papers on large language models (LLMs) in medicine have accumulated nearly fifteen thousand citations, creating ...
Analysis of the DHHS “Real Food” Initiative
EXECUTIVE SUMMARY The Department of Health and Human Services has launched a transformative public health initiative through the RealFood.gov platform, ...
Official MAHA Report
Explore the official MAHA Report released by the White House in May 2025.
Many famous painters struggled with mental health disorders
These include many of your favorite artists!
Romanticizing death in the age of Tuberculosis
Tuberculosis is a disease that spread widely in the 19th century. The art that stemmed from depictions of the disease ...
How do you envision death?
As society entered the era of modern medicine, people developed a new understanding of death. Artist John Downman portrays two ...
Can you guess the medical condition?
European nobles were famous for their inbreeding. Can you guess the conditions of Charles II of Spain (1661-1700)?
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...
Read morePopular
-
The Information Epidemic: How Digital Health Misinformation Is Rewiring Clinical Risk
-
Child Health Is Now a Platform Issue
-
Prevention Is Having a Moment and a Measurement Problem
-
Behavioral Health Is Now a Network Phenomenon
-
The Breach Is the Diagnosis: Cybersecurity Has Become a Clinical Risk Variable
